Candida auris: An Emerging Yeast Pathogen Posing Distinct Challenges for Laboratory Diagnostics, Treatment, and Infection Prevention.
Context.--Candida auris is an emerging yeast species that was first described in 2009. This ascomycetous yeast is notable for resistance to azole antifungal agents, for environmental persistence, and for its ability to contaminate health care environments, resulting in patient colonization and nosoc...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 144; no. 1; pp. 107 - 115 |
|---|---|
| Autores principales: | , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Jan2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=140960450&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 140960450 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Jan2020 vid: 144 iid: 1 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 140960450 140960450 140960450 10.5858/arpa.2018-0508-RA 140960450 ppf: 107 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Candida auris: An Emerging Yeast Pathogen Posing Distinct Challenges for Laboratory Diagnostics, Treatment, and Infection Prevention. aug: au: Hata, D. Jane Humphries, Romney Lockhart, Shawn R. affil: Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida sug: subj: Knowledge Evaluation Candidiasis Diagnosis Candidiasis Drug Therapy Candidiasis Prevention and Control Cross Infection Prevention and Control Candida Auris Antifungal Agents Therapeutic Use Candidiasis Microbiology Candidiasis Transmission Infection Control Systematic Review Microbial Contamination ab: Context.--Candida auris is an emerging yeast species that was first described in 2009. This ascomycetous yeast is notable for resistance to azole antifungal agents, for environmental persistence, and for its ability to contaminate health care environments, resulting in patient colonization and nosocomial infections. Objective.--To review the state of current knowledge addressing challenges in the accurate identification of C auris in the diagnostic microbiology laboratory, including application of phenotypic, proteomic, and genomic methodologies; characteristics that may predispose the human host to acquiring C auris; transmission; clinical presentations; treatment modalities; environmental decontamination; and infection prevention in health care settings. Data Sources.--The PubMed search engine was used to access peer-reviewed literature published from 2009 to 2019. Conclusions.--The rapid emergence of Cauris has presented unique challenges for the areas of laboratory diagnostics and infection prevention and in options for antifungal treatment, which are limited. The current lack of established antifungal susceptibility test breakpoints complicates therapeutic decision making. Enhanced awareness of this pathogen is essential to monitor outbreaks and to reduce the risk of spread within health care environments. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|